Editas Medicine (EDIT) was Initiated by Jefferies to “Hold”. Jefferies advised their investors in a research report released on Jun 2, 2016.
On the company’s financial health, Editas Medicine reported $-0.80 EPS for the quarter, missing the analyst consensus estimate by $ -0.48 based on the information available during the earnings call on May 16, 2016. Analyst had a consensus of $-0.32. The company had revenue of $.80 million for the quarter, compared to analysts expectations of $1.08 million.